Effect of diabetes-specific oral nutritional supplements with allulose on weight and glycemic profiles in overweight or obese type 2 diabetic patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
BACKGROUND/OBJECTIVES: Diabetes-specific oral nutritional supplements (ONS) have anti-hyperglycemic effects, while D-allulose exerts anti-diabetic and anti-obesity effects. In this study, we investigated the efficacy and safety of diabetes-specific ONS, including allulose, on glycemic and weight changes in overweight or obese patients with type 2 diabetes mellitus (T2DM). SUBJECTS/METHODS: A single-arm, historical-control pilot clinical trial was conducted on 26 overweight or obese patients with T2DM (age range: 30–70 yrs). The participants were administered 2 packs of diabetes-specific ONS, including allulose (200 kcal/200 mL), every morning for 8 weeks. The glycemic profiles, obesity-related parameters, and lipid profiles were assessed to evaluate the efficacy of ONS. RESULTS: After 8 weeks, fasting blood glucose (FBG) level significantly decreased from 139.00 ± 29.66 mg/dL to 126.08 ± 32.00 mg/dL (P = 0.007) and glycosylated hemoglobin (HbA1c) improved (7.23 ± 0.82% vs. 7.03 ± 0.69%, P = 0.041). Moreover, the fasting insulin (δ: −1.81 ± 3.61 μU/mL, P = 0.017) and homeostasis model assessment for insulin resistance (HOMA-IR) (δ: −0.87 ± 1.57, P = 0.009) levels decreased at 8 weeks, and body weight significantly decreased from 67.20 ± 8.29 kg to 66.43 ± 8.12 kg (P = 0.008). Body mass index (BMI) also decreased in accordance with this (from 25.59 ± 1.82 kg/m2 to 25.30 ± 1.86 kg/m2 , P = 0.009), as did waist circumference (δ: −1.31 ± 2.04 cm, P = 0.003). CONCLUSIONS: The consumption of diabetes-specific ONS with allulose in overweight or obese patients with T2DM improved glycemic profiles, such as FBG, HbA1c, and HOMA-IR, and reduced body weight and BMI.
Abstract
BACKGROUND/OBJECTIVES: Diabetes-specific oral nutritional supplements (ONS) have anti-hyperglycemic effects, while D-allulose exerts anti-diabetic and anti-obesity effects. In this study, we investigated the efficacy and safety of diabetes-specific ONS, including allulose, on glycemic and weight changes in overweight or obese patients with type 2 diabetes mellitus (T2DM). SUBJECTS/METHODS: A single-arm, historical-control pilot clinical trial was conducted on 26 overweight or obese patients with T2DM (age range: 30–70 yrs). The participants were administered 2 packs of diabetes-specific ONS, including allulose (200 kcal/200 mL), every morning for 8 weeks. The glycemic profiles, obesity-related parameters, and lipid profiles were assessed to evaluate the efficacy of ONS. RESULTS: After 8 weeks, fasting blood glucose (FBG) level significantly decreased from 139.00 ± 29.66 mg/dL to 126.08 ± 32.00 mg/dL (P = 0.007) and glycosylated hemoglobin (HbA1c) improved (7.23 ± 0.82% vs. 7.03 ± 0.69%, P = 0.041). Moreover, the fasting insulin (δ: −1.81 ± 3.61 μU/mL, P = 0.017) and homeostasis model assessment for insulin resistance (HOMA-IR) (δ: −0.87 ± 1.57, P = 0.009) levels decreased at 8 weeks, and body weight significantly decreased from 67.20 ± 8.29 kg to 66.43 ± 8.12 kg (P = 0.008). Body mass index (BMI) also decreased in accordance with this (from 25.59 ± 1.82 kg/m2 to 25.30 ± 1.86 kg/m2 , P = 0.009), as did waist circumference (δ: −1.31 ± 2.04 cm, P = 0.003). CONCLUSIONS: The consumption of diabetes-specific ONS with allulose in overweight or obese patients with T2DM improved glycemic profiles, such as FBG, HbA1c, and HOMA-IR, and reduced body weight and BMI.
참고문헌 (40)
- World Health Organization, "Global Health Estimates 2015: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2015" (2016), World Health Organization
- Saeedi P, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition", Diabetes Res Clin Pract, 157, pp.107843~ (2019)
- "Causes of death statistics" (2019)[URL]
- Choi YJ, "Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998–2005", Diabetes Care, 32, pp.2016~2020 (2009)
- 정찬희, "Diabetes Fact Sheets in Korea, 2020: An Appraisal of Current Status", Diabetes and Metabolism Journal, 45(1), pp.1~10 (2021), 대한당뇨병학회[DOI]
- American Diabetes Association, "2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021", Diabetes Care, 44, pp.S15~S33 (2021)
- 허규연, "2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association", Diabetes and Metabolism Journal, 45(4), pp.461~481 (2021), 대한당뇨병학회[DOI]
- Kang MR, "Use of oral nutritional supplements for patients with diabetes", J Korean Diabetes, 18, pp.181~188 (2017)
- de Luis DA, "A randomized clinical trial with two enteral diabetes-specific supplements in patients with diabetes mellitus type 2 : metabolic effects", Eur Rev Med Pharmacol Sci, 12, pp.261~266 (2008)
- de Luis DA, "A randomized clinical trial with two doses of an enteral diabetes-specific supplements in elderly patients with diabetes mellitus type 2", Eur Rev Med Pharmacol Sci, 17, pp.1626~1630 (2013)
- Mayr P, "A diabetes-specific oral nutritional supplement improves glycaemic control in type 2 diabetes patients", Exp Clin Endocrinol Diabetes, 124, pp.401~409 (2016)
- Jiang S, "Review on D-allulose : in vivo metabolism, catalytic mechanism, engineering strain construction, bio-production technology", Front Bioeng Biotechnol, 8, pp.26~ (2020)
- "Generally recognized as safe" (2011)[URL]
- Hossain A, "Rare sugar D-allulose : potential role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitus", Pharmacol Ther, 155, pp.49~59 (2015)
- Chung YM, "Dietary D-psicose reduced visceral fat mass in high-fat diet-induced obese rats", J Food Sci, 77, pp.H53~H58 (2012)
- Han Y, "A preliminary study for evaluating the dose-dependent effect of D-allulose for fat mass reduction in adult humans : a randomized, doubleblind, placebo-controlled trial", Nutrients, 10, pp.160~ (2018)
- Alish CJ, "A diabetes-specific enteral formula improves glycemic variability in patients with type 2 diabetes", Diabetes Technol Ther, 12, pp.419~425 (2010)
- Elia M, "Enteral nutritional support and use of diabetes-specific formulas for patients with diabetes : a systematic review and meta-analysis", Diabetes Care, 28, pp.2267~2279 (2005)
- Matthews DR, "Homeostasis model assessment : insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)
- 오지연, "한국어판 단문형 국제신처활동설문(IPAQ)의 신뢰도와 타당도", Korean Journal of Family Medicine, 28(7), pp.532~541 (2007), 대한가정의학회
- Davis SR, "Understanding weight gain at menopause", Climacteric, 15, pp.419~429 (2012)
- Weickert MO, "Metabolic effects of dietary fiber consumption and prevention of diabetes", J Nutr, 138, pp.439~442 (2008)
- Pohl M, "Glycemic control in patients with type 2 diabetes mellitus with a disease-specific enteral formula : stage II of a randomized, controlled multicenter trial", JPEN J Parenter Enteral Nutr, 33, pp.37~49 (2009)
- Pohl M, "Glycaemic control in type II diabetic tube-fed patients with a new enteral formula low in carbohydrates and high in monounsaturated fatty acids : a randomised controlled trial", Eur J Clin Nutr, 59, pp.1221~1232 (2005)
- Ojo O, "The effect of diabetes-specific enteral nutrition formula on cardiometabolic parameters in patients with type 2 diabetes : a systematic review and meta–analysis of randomised controlled trials", Nutrients, 11, pp.1905~ (2019)
- Ojo O, "Evaluation of the role of enteral nutrition in managing patients with diabetes : a systematic review", Nutrients, 6, pp.5142~5152 (2014)
- Evert AB, "Nutrition therapy for adults with diabetes or prediabetes : a consensus report", Diabetes Care, 42, pp.731~754 (2019)
- Qian F, "Metabolic effects of monounsaturated fatty acid–enriched diets compared with carbohydrate or polyunsaturated fatty acid–enriched diets in patients with type 2 diabetes : a systematic review and meta-analysis of randomized controlled trials", Diabetes Care, 39, pp.1448~1457 (2016)
- Huo R, "Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals : a meta-analysis", Eur J Clin Nutr, 69, pp.1200~1208 (2015)
- Ye Z, "Soluble dietary fiber(Fibersol-2)decreased hunger and increased satiety hormones in humans when ingested with a meal", Nutr Res, 35, pp.393~400 (2015)
- 한재흠, "대두 식이섬유를 이용한 특수 영양식품의 유효성 평가", Korean Journal of Agricultural Science, 35(1), pp.41~51 (2008), 농업과학연구소
- Howarth NC, "Dietary fiber and weight regulation", Nutr Rev, 59, pp.129~139 (2001)
- Magnoni D, "Long-term use of a diabetes-specific oral nutritional supplement results in a low-postprandial glucose response in diabetes patients", Diabetes Res Clin Pract, 80, pp.75~82 (2008)
- Vaisman N, "Tube feeding with a diabetes-specific feed for 12 weeks improves glycaemic control in type 2 diabetes patients", Clin Nutr, 28, pp.549~555 (2009)
- Mustad VA, "Use of a diabetes-specific nutritional shake to replace a daily breakfast and afternoon snack improves glycemic responses assessed by continuous glucose monitoring in people with type 2diabetes : a randomized clinical pilot study", BMJ Open Diabetes Res Care, 8, pp.e001258~ (2020)
- Pedersen E, "Effect of carbohydrate restriction in the first meal after an overnight fast on glycemic control in people with type 2 diabetes : a randomized trial", Am J Clin Nutr, 104, pp.1285~1291 (2016)
- Monnier L, "Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes : is this of concern?", Diabetes Care, 36, pp.4057~4062 (2013)
- Franc S, "Can postprandial blood glucose excursion be predicted in type 2 diabetes?", Diabetes Care, 33, pp.1913~1918 (2010)
- 김은경, "2020 한국인 에너지필요추정량 설정 및 앞으로의 과제", Journal of Nutrition and Health, 54(6), pp.573~583 (2021), 한국영양학회[DOI]
- Bonelli A, "Safety and tolerability of a novel oral nutritional supplement in healthy volunteers", Clin Nutr, 40, pp.946~955 (2021)